Background:
The liver is an important organ in cardio-kidney-metabolic (CKM) disease because of its essential roles in glucose homeostasis, cholesterol synthesis, and drug metabolism. We evaluated whether baseline liver fibrosis risk, estimated using the Fibrosis-4 (FIB-4) index, influenced treatment responses to es...
R. Helseth, J. Green, J. McGill et al.· Circulation· 0 citations
BACKGROUND
Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, reduces risk of heart and kidney outcomes in people with chronic kidney disease (CKD) and type 2 diabetes (T2D). Heart failure is the leading cause of hospitalization in patients with CKD. Here we evaluated whether the reduction in estimated g...
T. Shafi, S. Anker, B. Pitt et al.· European Journal of Heart Fa...· 0 citations
BACKGROUND
Patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) face high but modifiable risks of incident heart failure (HF). We aimed to ascertain whether the HFpEF-ABA score, a simple 3-variable tool to facilitate timely diagnosis of HFpEF, is associated with adverse cardiovascular (CV) outcomes in p...
R. Inciardi, J. Ostrominski, B. Claggett et al.· Journal of Cardiac Failure· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.